New combo attack on deadly brain tumors shows early promise
NCT ID NCT07193654
First seen Nov 01, 2025 · Last updated Jun 17, 2026 · Updated 31 times
Summary
This study tests whether adding a chemotherapy drug (thiotepa) directly into the spinal fluid can help control glioblastoma that has spread to the brain's lining or fluid spaces. About 38 adults with newly diagnosed, aggressive brain tumors will receive standard radiation and oral chemo plus the extra spinal injections. The goal is to see if this combination delays tumor growth and extends survival, while monitoring side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA (GBM) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
2nd Affiliated Hospital, School of Medicine
RECRUITINGHangzhou, Zhejiang, 310000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.